PRESS RELEASE published on 01/20/2026 at 18:30, 6 months 21 days ago Informations privilégiées / Autres communiqués MaaT Pharma annonce la randomisation du premier patient dans IMMUNOLIFE, essai Phase 2 promu par Gustave Roussy évaluant le rôle du microbiote pour contourner la résistance aux ICI chez des patients CPNPC avancé avec dysbiose liée aux antibiotiques Essai Clinique Microbiote MaaT Pharma Cancer Du Poumon IMMUNOLIFE
PRESS RELEASE published on 01/20/2026 at 18:30, 6 months 21 days ago Inside Information / Other news releases MaaT Pharma announces first patient randomized in IMMUNOLIFE Phase 2 study sponsored by Gustave Roussy to explore the role of gut microbiome in overcoming ICI resistance in NSCLC patients with antibiotic-induced dysbiosis NSCLC MaaT Pharma Gut Microbiome Antibiotic-induced Dysbiosis IMMUNOLIFE
BRIEF published on 12/10/2025 at 11:30, 8 months ago MaaT Pharma SACA Maintains Positive Outlook as Phase 3 Trial Data Strengthens Buy Recommendation Phase 3 Trial MaaT Pharma Xervyteg GI-aGvHD
BRIEF published on 12/10/2025 at 11:30, 8 months ago MaaT Pharma SACA maintient des perspectives positives alors que les données de l'essai de phase 3 se renforcent. Recommandation D'achat Essai De Phase 3 MaaT Pharma Xervyteg GI-aGvHD
PRESS RELEASE published on 12/10/2025 at 11:25, 8 months ago Original-Research: MaaT Pharma SACA (von First Berlin Equity Research GmbH): BUY First Berlin Equity Research updates recommendation to BUY for MaaT Pharma SACA with a target price of €17 following positive phase 3 trial results for Xervyteg presented at ASH Annual Meeting 2025 First Berlin Equity Research Buy Recommendation ASH Annual Meeting Xervyteg MaaT Pharma SACA
BRIEF published on 11/21/2025 at 11:27, 8 months 19 days ago Franchissement de Seuils chez MAAT PHARMA Droits De Vote Augmentation De Capital Franchissement De Seuils MaaT Pharma Invus Public Equities
BRIEF published on 11/21/2025 at 11:27, 8 months 19 days ago Crossing Thresholds at MAAT PHARMA Voting Rights Capital Increase Crossing Thresholds MaaT Pharma Invus Public Equities
PRESS RELEASE published on 11/21/2025 at 11:22, 8 months 19 days ago Franchissement de seuils Déclaration de franchissement de seuils par Invus Public Equities1, L.P. concernant MAAT PHARMA sur Euronext Paris. Augmentation de capital. Détention de 6,24% du capital et des droits de vote Euronext Paris Augmentation De Capital Franchissement De Seuils MaaT Pharma 6,24%
BRIEF published on 11/19/2025 at 11:16, 8 months 21 days ago MaaT Pharma Secures Capital to Support Commercialization Efforts Capital Increase MaaT Pharma Biotech Investment Xervyteg AGvHD Treatment
BRIEF published on 11/19/2025 at 11:16, 8 months 21 days ago MaaT Pharma obtient des capitaux pour soutenir ses efforts de commercialisation Augmentation De Capital MaaT Pharma Investissement En Biotechnologie Xervyteg Traitement De La GVHD Aiguë
Published on 08/11/2026 at 00:40, 2 hours 20 minutes ago CORRECTION FROM SOURCE: Fermi Announces Binding Lease Agreement with TensorWave
Published on 08/11/2026 at 00:25, 2 hours 35 minutes ago Empress Reports 2026 Second Quarter Financial Results
Published on 08/10/2026 at 23:35, 3 hours 25 minutes ago NioCorp Project to Expand Production to 8 Made-in-USA Critical Minerals Over a 40-Year Mine Life with an Estimated $4.1 Billion Pre-Tax NPV8%
Published on 08/10/2026 at 23:30, 3 hours 30 minutes ago Condor and Element79 Agree on Restructured Terms for Lucero Project
Published on 08/10/2026 at 23:25, 3 hours 35 minutes ago Ur-Energy Reports Second Quarter 2026 Results
Published on 08/10/2026 at 22:15, 4 hours 45 minutes ago Amrize Files Form 10-Q for Second Quarter 2026
Published on 08/10/2026 at 22:05, 4 hours 55 minutes ago Immunic Appoints Elena Ridloff to Board of Directors
Published on 08/10/2026 at 20:24, 6 hours 36 minutes ago EQS-Adhoc: PNE AG updates on ongoing sales process
Published on 08/10/2026 at 19:35, 7 hours 25 minutes ago Kontron AG: All conditions of the mandatory tender offer of Ennoconn Corporation are met – Settlement will take place shortly
Published on 08/10/2026 at 19:00, 8 hours ago PATRIMOINE ET COMMERCE: Déclaration des transactions sur actions propres (Hors contrat de liquidité) réalisées du 03 AOUT 2026 au 07 AOUT 2026
Published on 08/10/2026 at 18:00, 9 hours ago AXA: Information relating to the number of voting rights and shares making up the share capital on 31/07/2026
Published on 08/10/2026 at 18:00, 9 hours ago AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/07/2026
Published on 08/10/2026 at 17:45, 9 hours 15 minutes ago Déclaration hebdomadaire de rachat d'actions
Published on 08/10/2026 at 11:53, 15 hours 6 minutes ago GUILLEMOT CORPORATION | Information regarding the total number of voting rights and shares 31/07/2026
